Cycle Pharmaceutical Ltd (Cycle) is a pioneering pharmaceutical company, reimagining how drugs can benefit patients, to make their lives easier and improve their quality of life at every stage.
Cycle has three core areas of pharmaceutical development: improving orphan drugs (optimising an existing drug); repurposing drugs (creating a new indication for an already existing drug) and generics (reinstating generic drugs, previously available in the market). These three areas of focus are underpinned by formulation technology creating new drug delivery technologies to improve the efficacy and effectiveness of drugs, allowing Cycle to give patients greater freedom and choice.
With headquarters in Cambridge, U.K., and offices in Boston (MA) U.S, Cycle has developed unique partnerships with renowned universities and commercial companies around the world. Cycle is not limited to any one disease area. We are actively working in a broad range of disease areas, from cardiovascular and inflammatory conditions, to rare diseases such as cystic fibrosis and tyrosinemia type 1 (HT-1).
Company: | Cycle Pharmaceuticals Limited | |
Headquarters Address: | The Bailey Grundy Barrett Building | |
Little St Mary's Lane | ||
Cambridge CB2 1RR | ||
United Kingdom | ||
Main Telephone: | 44 (0) 1223 803636 | |
Website: | https://www.cyclepharma.com | |
Type of Organization: | Private | |
Industry: | Pharmaceutical | |
Key Executives: | CEO: Antonio Benedetti | |
Chairman: James Harrison | ||
Business Development: Steve Fuller | ||
Global Marketing | ||
Contact: | Paula Bekinschtein | |
Email: | info@cyclepharma.com | |
General Counsel | ||
Contact: | Sarah Gowing | |
Phone: | +44 (0) 1223 354118 | |
Email: | info@cyclepharma.com |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005498/en/
